A drug used to treat Hodgkin lymphoma in patients who did not get better with other treatment, cannot be treated with autologous stem cell transplant (ASCT), or have a high risk that the cancer will come back or get worse after ASCT. It is also used to treat systemic anaplastic large cell lymphoma that did not get better with other treatment. It is also being studied in the treatment of other types of lymphoma. Brentuximab vedotin is made up of a monoclonal antibody linked to an anticancer drug. It binds to a protein called CD30, which is on the surface of some lymphoma cells, and may kill cancer cells. Brentuximab vedotin is a type of antibody-drug conjugate. Also called Adcetris and SGN-35.